时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
However, recent evidence does not support an association between subclinical thyroid dysfunction and diabetes incidence ().；Metformin is widely prescribed in PMOS to improve insulin sensitivity; however, treatment during pregnancy has not reduced the incidence of GDM, altered gestational age at diagnosis of GDM, lowered fasting or 2-hour glucose levels, or reduced the need for additional insulin ().；It remains unknown whether longitudinal changes in thyroid hormone status influence parameters of insulin resistance during pregnancy in women with PMOS, or whether metformin modifies these associations.
方法
Both original trials utilized a double-blind, placebo-controlled, randomized design and followed nearly identical protocols.；Participants were assigned to either a placebo group or a metformin group, with treatment commencing during the first trimester and continuing until birth.；Daily metformin dosages differed slightly between the two cohorts, with the Pilot group receiving 1700 mg and the PregMet group receiving 2000 mg.；The flowchart of eligible women, exclusions, and the final cohort of randomized participants are shown in .
核心结论
TPO-antibody positivity did not change significantly from inclusion to the end of follow-up.；In descriptive comparisons, TPO-antibody positive and TPO-antibody negative women did not differ significantly in glucose, insulin, or HOMA-IR at the assessed gestational time points.；TPO-antibody positive women had slightly higher baseline TSH than TPO-antibody negative women, although TSH values remained within the reference range. ‖ 结论：These findings should be considered hypothesis-generating and require confirmation in future studies designed to elucidate possible underlying mechanisms for these associations in this specific population.
局限
This lack of effect has previously been reported in studies of pregnant women with PMOS.；Whether maternal thyroid parameters provide incremental predictive information beyond established metabolic risk factors, such as BMI and baseline HOMA-IR, remains to be determined in future studies.；Thus, the present findings should be interpreted as demonstrating longitudinal associations rather than establishing clinical utility for metabolic risk stratification.
对本项目的价值
★☆☆☆☆ 代谢轴既干预敏感性最高，也是老药新用供给最充足的来源。设计 randomized controlled trial。
全文来源
PMC JATS 全文（正文 25,927 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Maternal thyroid function and subsequent markers of insulin resistance in pregnant women with polyendocrine metabolic ovarian syndrome.
- 期刊与标识：Front Endocrinol (Lausanne) · PMID 42964126 · DOI 10.3389/fendo.2026.1884684
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。